Why Alvotech’s New Debt Facility Matters for Investors

Alvotech (NasdaqGM:ALVO) has amended its credit agreement to add a new term loan facility of up to $75 million, following a recent $165 million equity raise. This provides the company with additional financial flexibility.

Taken together, the undrawn term loan and the fresh equity funding provide Alvotech with access to $240 million in new capital. The company plans to use this to support its biosimilar pipeline, upcoming product launches and broader global commercialization efforts.

Despite the fresh capital, Alvotech’s share price has been under pressure, falling 20.86% over the past 30 days and 34.00% year to date. The 1 year total shareholder return is down 60.76%, pointing to fading momentum as the market reassesses both growth potential and risk.

Given how sentiment around Alvotech is shifting, it can be useful to compare it with other opportunities in healthcare, especially companies using AI to reshape treatment and drug development. This could be a good moment to review 40 healthcare AI stocks

After a 60.76% decline in 1 year total shareholder return, Alvotech now trades far below analyst price targets, so the key issue is whether most of the potential recovery lies ahead or is already reflected in the stock price.

Most Popular Narrative: 76.1% Undervalued

With Alvotech closing at $3.30 against a narrative fair value of $13.83, the gap between model and market is wide enough to catch investors’ attention.

Ongoing launch and approval pipeline activity, including upcoming regulatory decisions in major global markets (for AVT03, AVT05, AVT23, and others), positions the company to tap into blockbuster biologic markets coming off patent, potentially driving a step-change in topline revenue once approvals are secured.

Want to see what kind of revenue curve and margin profile justify that valuation gap? The core narrative leans on aggressive scaling, richer profitability and a premium future earnings multiple.

Result: Fair Value of $13.83 (UNDERVALUED)

However, there are still real pressure points for the Alvotech narrative, including heavy reliance on unpredictable milestone payments and a high debt load that could strain liquidity.

Next Steps

Given the mixed sentiment around Alvotech, with both clear concerns and some potential upside, this is a moment to look at the numbers directly and decide where you stand using 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Alvotech?

If Alvotech has sharpened your focus on risk, reward and valuation, do not stop here. Broaden your watchlist with a few targeted ideas built from data driven screens.

• Spot potential turnaround candidates by scanning higher risk opportunities using 20 elite penny stocks with strong financials.
• Prioritize value by checking companies that combine quality fundamentals with attractive pricing through 44 high quality undervalued stocks.
• Strengthen your defensive side by reviewing resilient companies that aim for stability using 79 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.